Genetic and vascular disorder treatment company Clinuvel Pharmaceuticals (ASX:CUV) released a new strategic update on Monday.
The firm plans to expand its research capabilities for skin cancer treatments and damage remediation. The establishment of a new manufacturing division is on the company’s strategic agenda to advance new treatment formulas.
The strategic update has done little to boost investor appetite, as shares in Clinuvel Pharmaceuticals are trading 2.42 per cent lower at $29.39 .
Copyright 2021 – Finance News Network
12 May 2021 - A snapshot of company news making headlines in the morning session, featuring Commonwealth (ASX:CBA), Carsales (ASX:CAR) & Evolution Mining (ASX:EVN).
05 Sep 2019 - Spark (ASX:SPK) owned subsidiary Qrious has finalised the acquisition of NOW Consulting, the New Zealand-based data consulting division of WhereScape Software.
01 May 2020 - Industrials heavyweight Reliance Worldwide Corporation (ASX:RWC) has announced that due to the impact of covid-19 the board has decided to scale back manufacturing operations in Australia from 5 days a week to 4 days a week, commencing the week of 11 May 2020.
13 Sep 2019 - The ACCC has issued a draft determination proposing to authorise Virgin Australia (ASX:VAH) to more closely cooperate with Virgin Atlantic on flights between Australia and the UK and Ireland, via Hong Kong, Los Angeles and any other future mutual connecting points.
21 Apr 2020 - Virgin Australia (ASX:VAH) has entered voluntary administration but will continue to operate its scheduled international and domestic flights to help essential workers and Australians returning home.
25 Oct 2019 - Ship manufacturer, Austal (ASX:ASB) has penned a contract for the design and construction of a 115 metre, high-speed catamaran for Molslinjen of Denmark.
16 Sep 2020 - Decmil Group (ASX:DCG) is pleased to announce that it has been awarded around $41 million contract for an iron bridge in the Pilbara region of Western Australia.
